A rare malaria victory

Written byBob Grant

| 2 min read

I've been looking into how global health programs evaluate the effects of their interventions for a story that will appear in our March issue. Public health experts have told me again and again that too little attention has been paid to evaluation across the board. This morning (Feb.1), both linkurl:__The Washington Post__;http://www.washingtonpost.com/wp-dyn/content/article/2008/01/31/AR2008013101943.html?wpisrc=newsletter and linkurl:__The New York Times__;http://www.nytimes.com/2008/02/01/health/01malaria.html?_r=1&ref=world&oref=slogin reported on a study by the World Health Organization that seems to address this issue. The study looked at how well distributing of insecticide-treated bed nets and linkurl:artemisinin,;http://www.the-scientist.com/article/display/36878/ the newest anti-malarial drug, affected rates of child malaria deaths in Ethiopia, Ghana, Rwanda, and Zambia. The team found that children's deaths from malaria have dropped by about 50 percent in Ethiopia, where 20 million nets were distributed over two years, and by more than 60 percent in Rwanda, where two million nets were distributed over two months in 2006. The 33 percent decline in malaria deaths among Zambian children would have been greater if supplies of nets and drugs hadn't run out in many areas, the report suggests. Data from Ghana, though, seemed a bit more puzzling. Ghana received little funding from the Global Fund, which heavily subsidized programs in the other three countries. This meant that Ghana was not able to buy many bed nets and had to charge patients for drugs. But still, the country saw a 34 percent decrease in child malaria deaths. The study got its data from local hospitals. It's an improvement over programs that don't do any follow-up monitoring of their programs at all. But I can't help but wonder what additional insights could have been gained from more thorough data collection and analysis. Counting deaths in malaria-stricken children is something, but tracking malaria infection rates in a wider segment of the Ghanaian population might have provided other explanations for the decrease in deaths, such as vector population declines or decreases in transmission rates. In other malaria news (that happens to intersect my fascination with linkurl:chimpanzees),;http://www.the-scientist.com/article/display/53392/ clinical trials on a malaria linkurl:vaccine;http://www.dailymail.co.uk/pages/live/articles/health/healthmain.html?in_article_id=511600&in_page_id=1774 based on a chimp virus have begun in the UK.

Meet the Author

Bob Grant

From 2017 to 2022, Bob Grant was Editor in Chief of The Scientist, where he started in 2007 as a Staff Writer. Before joining the team, he worked as a reporter at Audubon and earned a master’s degree in science journalism from New York University. In his previous life, he pursued a career in science, getting a bachelor’s degree in wildlife biology from Montana State University and a master’s degree in marine biology from the College of Charleston in South Carolina. Bob edited Reading Frames and other sections of the magazine.

View Full Profile

A rare malaria victory

The Scientist ARCHIVES

Become a Member of

Meet the Author

Bob Grant

Related Research Resources

What Causes an Earworm?

Research Resources

Podcasts

Webinars

Videos

Infographics

eBooks

Genome Modeling and Design: From the Molecular to Genome Scale

Screening 3D Brain Cell Cultures for Drug Discovery

Producing Tumor-infiltrating Lymphocyte Therapeutics

Weaving the Fabric of Cancer Research with Synthetic DNA

Products

Product News

Sino Biological Sets New Industry Standard with ProPure Endotoxin-Free Proteins made in the USA

Introducing the iQue 5 HTS Platform: Empowering Scientists with Unbeatable Speed and Flexibility for High Throughput Screening by Cytometry

Vanderbilt Selects Parse Biosciences GigaLab to Generate Atlas of Early Neutralizing Antibodies to Measles, Mumps, and Rubella

Shift Bioscience proposes improved ranking system for virtual cell models to accelerate gene target discovery